Agile Story

<div class='circular--portrait' style='background:#FF0F00;color: #FFFFF0;font-size:4em;'>AT</div>
AGRX -- USA Stock  

USD 2.88  0.08  2.86%

It appears Agile Therapeutics will continue to recover much faster as its share price surged up 15.92% today. This firm's current daily volatility is 3.92 percent, with a beta of 0.89 and an alpha of -0.11 over DOW. As many investors are getting excited about pharmaceutical products, it is fair to break down Agile Therapeutics. We will analyze why Agile Therapeutics investors may still consider a stake in the business.
Published over a month ago
View all stories for Agile Therapeutics | View All Stories
Should you keep an eye on Agile Therapeutics (NASDAQ:AGRX) management before September?
Agile Therapeutics conducts business under Healthcare sector and is part of Drug Manufacturers?Specialty & Generic industry.
Investing in Agile Therapeutics, just like investing in any other equity instrument, is characterized by a strong risk-return correlation. High risks mean high returns and low risk means lower expected returns. Risk management is the act of identifying and assessing the potential risk and developing strategies to minimize these risks and earn maximum possible profits while holding Agile Therapeutics along with other instruments in the same portfolio. Using conventional technical analysis and fundamental analysis to select individual securities into a portfolio complements risk management and adds value to overall investors' investing strategies.

How important is Agile Therapeutics's Liquidity

Agile Therapeutics financial leverage refers to using borrowed capital as a funding source to finance Agile Therapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Agile Therapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Agile Therapeutics's total debt and its cash.

How Agile utilizes its cash?

To perform a cash flow analysis of Agile Therapeutics, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Agile Therapeutics is receiving and how much cash it distributes out in a given period. The Agile Therapeutics cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Agile Therapeutics Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. Agile Therapeutics reported Net Cash Flow from Operations of (15.69 Million) in 2019

Agile Therapeutics Correlation with Peers

Investors in Agile can reduce exposure to individual asset risk by holding a diversified portfolio of assets in addition to a long position in Agile Therapeutics. Diversification will allow for the same portfolio return with reduced risk. The correlation table of Agile Therapeutics and its peers is a two-dimensional matrix that shows the correlation coefficient between pairs of securities Agile is related in some way. The cells in the table are color-coded to highlight significantly positive and negative relationships. Each cell shows the correlation between one pair of equities and can be used to run pair trading strategies or create efficient portfolios with your current brokerage. Please check volatility of Agile for more details

Exercise or conversion by Dennis Reilly of 37500 shares of Agile Therapeutics subject to Rule 16b-3

Legal trades by Agile Therapeutics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Agile insider trading alert for exercise of employee stock option (right to buy) by Dennis Reilly, Chief Financial Officer, on 26th of August 2020. This event was filed by Agile Therapeutics Inc with SEC on 2020-08-26. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

What is driving Agile Therapeutics Investor Appetite?

We consider Agile Therapeutics unstable. Agile Therapeutics secures Sharpe Ratio (or Efficiency) of 0.0189, which signifies that the company had 0.0189% of return per unit of risk over the last month. Our standpoint towards foreseeing the volatility of a stock is to use all available market data together with stock specific technical indicators that cannot be diversified away. We have found twenty-one technical indicators for Agile Therapeutics, which you can use to evaluate future volatility of the firm. Please confirm Agile Therapeutics Downside Deviation of 3.55, mean deviation of 2.84, and Risk Adjusted Performance of 0.0613 to double-check if the risk estimate we provide is consistent with the expected return of 0.0741%.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Our perspective of the current Agile Therapeutics rise

Current value at risk indicator falls down to -6.2. Possible price jump? Agile Therapeutics shows above-average downside volatility for the selected time horizon. We advise investors to inspect Agile Therapeutics further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Agile Therapeutics future alpha.

Our Final Take On Agile Therapeutics

While some other companies within the drug manufacturers?specialty & generic industry are still a little expensive, even after the recent corrections, Agile Therapeutics may offer a potential longer-term growth to investors. With an impartial outlook on the current market volatility, it may be better to hold off any inventment activity and neither acquire nor exit any shares of Agile Therapeutics at this time. The Agile Therapeutics risk-reward trade off is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Agile Therapeutics.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Agile Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com